Clinical trials: Tislelizumab
Hepatocellular Carcinoma (HCC), IrAE
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
This study is a prospective, randomized, single-center randomized controlled clinical trial to investigate the safety and efficacy of ondansetron in reducing the toxicity associated with immune checkpoint inhibitor treatment.
- Trial name
- NCT07381634
- Testing
- ondansetron
- Where
- China
- Volunteers
- 134 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Advanced Squamous Non-Small Cell Lung Carcinoma
TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.
This is Phase 3, randomized, double-blind, parallel controlled study designed to evaluate the Progression Free Survive (PFS) of TQB2450 injection combined with Paclitaxel Injection and Carboplatin Injection Followed by TQB2450…
- Trial name
- NCT05718167
- Testing
- TQB2450, Anlotinib hydrochloride capsule, Tislelizumab injection
- Where
- 4 sites in China
- Volunteers
- 570 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer
A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
The purpose of this study is to collect real-world data on treatment patterns and clinical outcomes in European patients receiving tislelizumab in routine clinical practice
- Trial name
- TITANS (NCT07652736)
- Testing
- Tislelizumab
- Where
- 6 sites in Spain
- Volunteers
- 440 people
- Sponsor
- BeOne Medicines
Tongue Squamous Cell Carcinoma
Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer
The goal of this clinical trial is to evaluate the feasibility and preliminary efficacy of lingual nerve disruption combined with neoadjuvant chemoimmunotherapy in patients with locally advanced tongue squamous cell carcinoma.
- Trial name
- NCT07346807
- Testing
- Lingual Nerve Disruption, Tislelizumab, Albumin-bound Paclitaxel
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma (HCC)
Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer
This study is for people with unresectable or advanced hepatocellular carcinoma who have not received previous systemic treatment for liver cancer. The study will compare lenvatinib plus tislelizumab with or without gefitinib.
- Trial name
- LENTIG-HCC (NCT07829926)
- Testing
- Lenvatinib, Tislelizumab, Gefitinib
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
MSI-H Colorectal Cancer, Tislelizumab
Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer
This study is a multi-center, single-arm, open-label phase II clinical trial, aiming to observe and evaluate the perioperative treatment of tislelizumab combined with chemotherapy (CAPOX) in stage II or III colorectal cancer with…
- Conditions
- MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin, Capecitabine
- Trial name
- NCT05841134
- Testing
- Tislelizumab
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Biliary Tract Carcinoma
GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma
In this phase 2 study, the investigators aim to evaluate the effects and safety of combined therapy using oxaliplatin and gemcitabine chemotherapy, Donafenib and Tislelizumab for patients with advanced biliary tract carcinoma.
- Trial name
- NCT05668884
- Testing
- Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Fudan University
Advanced Solid Tumor
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Open-label, two parallel arm, multicenter, Phase 1 dose-escalation study to evaluate the safety and tolerability of OMTX705, both as monotherapy or in combination with pembrolizumab (Part 1) or tislelizumab (Part 2) in the…
- Trial name
- NCT05547321
- Testing
- OMTX705, Pembrolizumab, Tislelizumab (BGB-A317)
- Where
- 9 sites in United States, Spain
- Volunteers
- 150 people
- Sponsor
- Oncomatryx Biopharma S.L.
Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel, to determine the…
- Conditions
- Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
- Trial name
- NCT05768932
- Testing
- BAL0891, Tislelizumab, Paclitaxel
- Where
- 17 sites in United States, South Korea
- Volunteers
- 260 people
- Sponsor
- SillaJen, Inc.
NSCLC (Advanced Non-small Cell Lung Cancer)
A Retrospective Real-World Study Based on RATIONALE-307
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in…
- Trial name
- NCT07478809
- Testing
- No intervention
- Where
- China
- Volunteers
- 109 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma (HCC)
TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with Tislelizumab and Lenvatinib in patients with advanced-stage hepatocellular carcinoma (HCC).
- Trial name
- CHANCE2602 (NCT07836309)
- Where
- China
- Volunteers
- 596 people
- Sponsor
- Zhongda Hospital
Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
This prospective, single-center, randomized controlled trial aims to assessing the efficacy and safety of neoadjuvant chemoradiation plus Tislelizumab (PD-1 inhibitor) with or without Probio-M9 and subsequent TME surgery, by…
- Conditions
- Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9
- Trial name
- NCRIT-PM9 (NCT07458529)
- Testing
- CRT+PD-1 inhibitor+Probio-M9
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Seventh Medical Center of PLA General Hospital
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage, Unresectable
Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma
Whether the introduction of immunotherapy can transform unresectable esophageal cancer into resectable, or even achieve R0 surgical resection, has not been reported yet.
- Trial name
- NCT05449483
- Testing
- tislelizumab+ Paclitaxel + Cisplatin
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Head and Neck Squamous Cell Carcinomas
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)
The trial is being conducted to evaluate the efficacy and safety of Tislelizumab in combination with dasatinib and quercetin(combining immunotherapy and senolytics, COIS) in patients with head and neck squamous cell carcinoma who…
- Trial name
- NCT05724329
- Testing
- Tislelizumab + Dasatinib + Quercetin (neoadjuvant), surgery, Tislelizumab + Dasatinib + Quercetin (adjuvant)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non-Muscle Invasive Bladder Cancer, HER2
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
This is a prospective, open, single-center clinical study of anti-HER2-ADC combined with PD-1 monoclonal antibody for bladder sparing treatment in non-muscular invasive bladder cancer (NMIBC) patients with HER2-expressing.
- Trial name
- NCT05957757
- Testing
- RC48, Tislelizumab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Solid Tumor
Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China
Main purpose: To evaluate the safety and tolerability of BAT6021 injection in the treatment of locally advanced or metastatic solid tumors with single drug or combined with tislelizumab(anti PD-1 monoclonal antibody); Explore the…
- Trial name
- NCT05120375
- Testing
- BAT6021
- Where
- 3 sites in China
- Volunteers
- 5 people
- Sponsor
- Bio-Thera Solutions
Immunotherapy, Colorectal Cancer
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
To evaluate the clinical efficacy and safety of TAS-102 combined with bevacizumab and tislelizumab in third-line or above treatment in patients with advanced colorectal adenocarcinoma with liver metastasis.
- Trial name
- NCT05314101
- Testing
- Tislelizumab, bevacizumab, TAS-102
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fujian Cancer Hospital
Advanced or Recurrent Solid Tumors
EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors
The goal of this clinical trial is to learn the side effects, safety and effect of a tumor vaccine (EVM16) alone or in combined with an anti-PD-1 antibody (tislelizumab) .
- Trial name
- NCT06541639
- Testing
- EVM16, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Peking University
Hepatocellular Carcinoma
A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma
Notable-HCC is a phase Ib study of neoadjuvant stereotactic body radiotherapy (SBRT) plus Programmed cell death-1 (PD-1, Tislelizumab, BeiGene) prior to hepatic resection in patients with resectable HCC.
- Trial name
- Notable-HCC (NCT05185531)
- Testing
- PD-1 plus stereotactic body radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shandong Cancer Hospital and Institute
Solid Tumor, Adult
Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus Lenvatinib for patients with previously treated solid tumors.
- Trial name
- CASTLE-11 (NCT06032845)
- Testing
- Tislelizumab, Lenvatinib, Cryoablation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University